Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue (2013 - 2016)

Amphastar Pharmaceuticals' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $830000.0 for Q3 2016.

• On a quarterly basis, Current Deferred Revenue rose 29.08% year-over-year to $830000.0 in Q3 2016; TTM through Sep 2016 was $830000.0, a 29.08% increase from a year earlier, with the FY2015 full-year figure at $643000.0, down 95.41% from the prior year.
• Current Deferred Revenue retreated to $830000.0 in Q3 2016 per AMPH's latest filing, from $1.7 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $14.6 million in Q3 2014 and bottomed at $643000.0 in Q4 2013.
• The 4-year median for Current Deferred Revenue is $830000.0 (2016), against an average of $4.1 million.
• Across the five-year window, Current Deferred Revenue jumped 2079.32% in 2014 and plunged 95.59% in 2015, its largest moves.
• Year by year, Current Deferred Revenue stood at $643000.0 in 2013, then soared by 2079.32% to $14.0 million in 2014, then slumped by 95.41% to $643000.0 in 2015, then increased by 29.08% to $830000.0 in 2016.
• Per Business Quant, the three latest AMPH Current Deferred Revenue figures stand at $830000.0 (Q3 2016), $1.7 million (Q2 2016), and $643000.0 (Q1 2016).